enGenes deploys X-press technology to modular prokaryotic protein expression services


enGenes deploys X-press technology to modular prokaryotic protein expression services


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

JANUARY 25, 2018

Vienna, Austria: – Recombinant protein specialist manufacturer and service provider enGenes Biotech GmbH (enGenes) has mobilized its proprietary X-press technology to support a new range of gene expression and prokaryotic protein production services.

The service portfolio is designed and structured on modular lines to provide a wide range of realistic options for companies looking to develop cost-effective manufacturing processes for recombinant proteins.

Step by step

The service model is focused on the expression of difficult-to-express proteins covering all specific demands along the line from gene to protein. It is divided into a series of steps that can be performed either individually or in combination – allowing customers to choose from a menu of the steps actually required, including:

  • Cloning and vector optimization
  • Generation of expression strain and host cell engineering
  • Feasibility studies for enGenes-X-press application
  • Lab scale fermentations and bioprocess optimization
  • Establishing purification protocol and final purification

X-press power

The protein expression and production elements are enhanced by the power of the world-leading enGenes-X-press technology for growth-decoupled protein production in Escherichia coli (E.coli). This has allowed enGenes to develop economic, scalable and efficient production processes within short time frames.

enGenes X-press has proven ability to achieve outstanding yields of soluble and active recombinant protein, radically improving on the existing T7 expression system. The technology is fully scaleable and can be operated at cell densities up to 100 g/L biomass, allowing high specific and volumetric yields. The production platform has already unlocked successful manufacture of enzymes and biopharmaceutical products that failed to give economically feasible yields in conventional expression hosts, such as BL21(DE3).

Optimized protein expression and bioprocess in E. coli

enGenes now offers a modular system of customer services for gene expression and protein production in Escherichia coli (E.coli) and other prokaryotes (e.g. Bacillus subtilis).

“Our world-leading enGenes-X-press™ technology for growth-decoupled protein production allows us to develop economic, scalable and efficient production processes within short time frames with the productivity power required to transform our customers’ unique products into commercial successes,” said enGenes Biotech CEO, Dr. Juergen Mairhofer.

enGenes recently announced a new collaboration with the Technical University of Vienna to apply the company’s proprietary enGenes-X-press™ technology to integrative bioprocess development for biosimilar production. The collaboration emphasizes enGenes’ strengths in Research & Development (R&D) and its vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost effective recombinant protein production processes, including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press™ has been successful applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707
Email: office@engenes.cc

Resources

Click on enGenes prokaryotic protein expression for more information.
Click on enGenes Biotech GmbH to contact the company directly.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


Comments are closed.